BiPAP Lawsuit: Philips Recall, Three Settlements, and MDL Status

If you used a recalled Philips BiPAP machine, a BiPAP lawsuit against Philips would fall under MDL 3014 in the Western District of Pennsylvania, where the company has agreed to pay more than $1.5 billion across three separate settlements covering device costs, personal injuries, and long-term medical monitoring.¹ Whether you can still collect depends on which track applies to your situation and whether you registered before the deadlines that have already run in the economic-loss and personal-injury programs.

Which BiPAP Devices Are Covered

The June 2021 recall swept in more than 20 product families manufactured between 2009 and April 26, 2021. The BiPAP models affected include the A-Series BiPAP A30 and A40, along with the broader DreamStation, DreamStation Go, REMstar, and Trilogy 100 and 200 ventilator lines.² In total, roughly 15 million devices worldwide fell under the action, which the FDA classified as Class I — its most serious category, reserved for situations involving potential severe injury or death.³

Why the Machines Were Recalled

The recalled devices used polyester-based polyurethane (PE-PUR) foam to dampen sound and vibration. In heat and humidity, or when users cleaned their machines with ozone-based products, the foam could degrade and release black particles and volatile organic compounds that users might inhale or swallow during sleep therapy.⁴ The FDA warned that foam breakdown “could potentially result in serious injury and may require medical intervention to prevent permanent injury” and rejected Philips’ own conclusion that harm was unlikely.⁵

Investigative reporting later showed Philips had received complaints about foam particles as early as 2010, and by the end of 2014 had logged more than 500 complaints about dust contamination and foam degradation. Internal communications in 2015 acknowledged that heat and humidity could cause the foam to break down within a year. Late-2020 internal health hazard evaluations by senior Philips officials rated the risk as “UNACCEPTABLE,” noting the crumbling foam could cause “serious injury, life-threatening or permanent impairment.” Over eleven years, Philips withheld more than 3,700 foam-related complaints from the FDA.⁶

Independent research on the health consequences is mixed. A 2022 European Respiratory Journal study of a Swedish cohort found mild worsening of obstructive lung disease control and increased use of respiratory medications among foam-exposed CPAP users, but called the cancer data “inconclusive” after adjusting for smoking. Lab testing did confirm that foam degradation products include toluene diamine and toluene di-isocyanate isomers, chemicals with known cyto- and genotoxic effects.⁷

The Economic Loss Settlement: Refunds for the Device

The first track compensates users for what they paid to buy, lease, or rent a defective machine. Judge Joy Flowers Conti granted final approval on April 25, 2024. The deal was characterized at a total value of $1.1 billion, with Philips committing to pay at least $445 million in direct device-related payments, up to $15 million for device replacement awards, and $34 million for third-party payer claims.⁸

Payments depend on the model. A basic System One paid about $69; a Trilogy ventilator paid roughly $1,552. Returning a recalled device added a $100 return award, and users who paid out of pocket for a replacement between June 2021 and September 2023 could claim a replacement award.⁸

The claims deadline was August 9, 2024. If you filed on time, payments have been issuing on a rolling basis.⁹ If you didn’t file, this fund is closed to you. Important to know: accepting an economic-loss payment does not waive personal injury or medical monitoring claims — those are separate tracks with separate rules.¹⁰

The Personal Injury Settlement: Compensation for Health Harm

On April 29, 2024, Philips reached a separate $1.075 billion agreement to resolve claims from users who alleged they developed cancer, respiratory disease, or other serious conditions from the degraded foam.¹¹ Unlike the economic loss deal, this is a private settlement program, not a class action. Each claim is evaluated individually by a settlement administrator, MDL Centrality.¹²

Who Qualifies

To qualify, a claimant must be a U.S. citizen or resident, must have used a recalled device, and must have been diagnosed with a qualifying injury by April 29, 2024. Qualifying injuries include lung, thyroid, kidney, and esophageal cancers, acute myeloid leukemia, and other cancers, plus respiratory conditions such as new-onset asthma, COPD, pulmonary fibrosis, and bronchiolitis obliterans.¹³

Registration Deadline

Claimants had to submit a registration packet by January 31, 2025, including signed forms, proof of device usage, and medical records supporting the diagnosis.¹⁴ That deadline has passed. Anyone who did not register cannot participate in this settlement fund.

How Awards Are Calculated

Claims move through either an Expedited Payment Program for simpler cases or a Full Evaluation Program using a point-based system. Full Evaluation awards range from 25 to 2,750 points, with a minimum gross payout of $4,000 at the lowest severity level. The dollar value per point cannot be finalized until all registrations are processed, because the $1.075 billion is a fixed fund shared across qualifying claimants. If 40,000 people qualify, the estimated average is roughly $26,875; if 30,000 qualify, approximately $35,000.¹³

An Extraordinary Injury Fund provides extra compensation for the most severe outcomes, including death, qualifying surgeries, or significant permanent impairment. The EIF application window opened in April 2025, with a submission deadline of August 1, 2025.¹³

Whether the Settlement Is Final

The agreement required at least 95% of eligible claimants to participate. The settlement administrator was to report on that threshold by February 14, 2025, and Philips’ right to walk away from the deal expired on February 28, 2025. If the agreement held, Philips was to deposit $1.05 billion into a Qualified Settlement Fund by March 14, 2025.¹⁴ Publicly available records as of mid-2026 do not confirm whether the participation threshold was met or whether the settlement has been finalized. If the deal collapses, bellwether trials could proceed.¹¹ The agreement contains no admission of liability, fault, or causation by Philips.¹²

The Medical Monitoring Settlement

The third track addresses long-term health surveillance for users who don’t yet have a diagnosed injury. Philips agreed to pay $25 million to fund a Medical Advancement Program (MAP) designed to operate for 15 years. The program does not pay cash to class members. It funds independent research into detection and treatment of qualifying injuries, creates a research registry, and builds an interactive website for ongoing health guidance.¹⁵

The parties sought conditional certification of a mandatory, non-opt-out nationwide settlement class for this track, with a preliminary approval hearing set for June 18, 2024.¹ Available docket records do not confirm final approval. Importantly, this settlement does not affect a class member’s right to pursue a personal injury lawsuit or seek individual monetary relief for medical monitoring.¹⁵

Current Status of the MDL

Thousands of lawsuits were consolidated into MDL 3014, formally titled In Re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation, before Senior U.S. District Judge Joy Flowers Conti. A parallel state-court track proceeded in Massachusetts Middlesex County Superior Court.¹² As of May 2026, 622 cases remained pending in the MDL. No bellwether trials have taken place; the parties moved toward settlement before any case reached a jury. Judge Conti was preparing bellwether selections after a March 2024 status conference as a backstop if settlement talks failed.¹¹

What If You Missed the Deadlines

The economic loss claim deadline (August 9, 2024) and personal injury registration deadline (January 31, 2025) have both passed. If you did not register in either program, you are outside those funds. Whether you retain any right to file an individual lawsuit depends on your state’s statute of limitations, the specific injury alleged, and whether you were bound by the mandatory medical monitoring class. Consult a lawyer familiar with MDL 3014 before assuming your claim is either alive or dead.

The FDA Consent Decree Is Separate

On April 9, 2024, U.S. District Judge Robert J. Colville entered a consent decree of permanent injunction against Philips RS North America LLC and affiliated entities and executives, including Philips CEO Roy Jakobs.¹⁶ The Department of Justice alleged that Philips manufactured and distributed adulterated and misbranded devices, failed to follow good manufacturing practices at Pennsylvania facilities, and failed to properly report corrections and removals to the FDA.¹⁷ The decree bars Philips from manufacturing or selling new sleep-therapy devices at its Pennsylvania and California facilities until it meets several remediation conditions and receives written FDA compliance notification.

This is a government enforcement action, not a compensation program. It does not pay money to BiPAP users, and it is not a path to recovery for individuals harmed by the recalled devices.

1
U.S. District Court for the Western District of Pennsylvania. MDL 3014
2
U.S. Food and Drug Administration. Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines
3
National Center for Biotechnology Information. Cancer Risk Associated With Continuous Positive Airway Pressure: A National Study
4
U.S. Food and Drug Administration. Foam Testing Summary Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines
5
U.S. Food and Drug Administration. CDRH Provides Update on Philips June 2021 Recall
6
ProPublica. Philips Kept Warnings About Dangerous CPAPs Secret as Profits Soared
7
European Respiratory Society. Health Risks Related to Polyurethane Foam Degradation in CPAP Devices Used for Sleep Apnoea Treatment
8
U.S. District Court for the Western District of Pennsylvania. Class Settlement Notice
9
Respironics CPAP EL Settlement. Respironics CPAP Economic Loss Settlement
10
NPR. CPAP Philips Sleep Apnea Injury Lawsuit
11
Drugwatch. Philips CPAP Lawsuits
12
ClassAction.org. In Re Philips CPAP Personal Injury Settlement
13
Respironics PI Settlement. Philips Respironics Personal Injury Settlement FAQs
14
Respironics PI Settlement. Philips Respironics Personal Injury Settlement
15
ClassAction.org. Philips CPAP Medical Monitoring Settlement Terms
16
U.S. Food and Drug Administration. Federal Court Enters Consent Decree Against Philips Respironics
17
U.S. Department of Justice. Court Enjoins Philips Respironics From Manufacturing and Distributing Adulterated and Misbranded Devices